India, Aug. 20 -- Active Biotech AB (publ) (ACTI.ST), an immunomodulatory treatment company, on Thursday announced interim financial results for the second quarter and registered a marginally lower loss as clinical trials ensued only prior to and after the period.
The Swedish company is advancing Tasquinimod for myelofibrosis, and Laquinimod in an eye drop formulation for treating uveitis, an inflammation of eye tissue. Naptumomab is also being developed with NeoTX Therapeutics as a tumor-directed immunotherapy for certain cancers.
Q2 Financial Updates:
The company's net loss shrunk to SEK 10.1 million in the second quarter of 2026, slightly lower than the SEK 11.2 million reported in the same period of 2025.
Earnings per share resulted...